

Fabiola Atzeni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6858965/publications.pdf>

Version: 2024-02-01

221
papers

7,298
citations

57758

44
h-index

76900

74
g-index

228
all docs

228
docs citations

228
times ranked

8288
citing authors

#	ARTICLE	IF	CITATIONS
1	The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. <i>Arthritis and Rheumatology</i> , 2015, 67, 568-575.	5.6	323
2	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , 2020, 16, 645-660.	8.0	279
3	Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2006, 119, 700-706.	1.5	278
4	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1755-1766.	1.9	201
5	Immunogenicity and autoimmunity during anti-TNF therapy. <i>Autoimmunity Reviews</i> , 2013, 12, 703-708.	5.8	167
6	Autoimmunity and Anti-TNF- α Agents. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 559-569.	3.8	150
7	Serious infections during anti-TNF- α treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 266-273.	5.8	148
8	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
9	Extraspinial manifestations of diffuse idiopathic skeletal hyperostosis. <i>Rheumatology</i> , 2009, 48, 1478-1481.	1.9	130
10	TNF- α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 837-846.	3.8	130
11	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128
12	Is atherosclerosis an autoimmune disease?. <i>BMC Medicine</i> , 2014, 12, 47.	5.5	122
13	TNF- α , rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005, 4, 153-161.	5.8	118
14	Etiology of fibromyalgia: The possible role of infection and vaccination. <i>Autoimmunity Reviews</i> , 2008, 8, 41-43.	5.8	116
15	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , 2006, 8, R3.	3.5	105
16	Cardiovascular involvement in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2009, 8, 281-286.	5.8	103
17	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. <i>Autoimmunity Reviews</i> , 2009, 8, 274-280.	5.8	101
18	Chronic widespread pain in the spectrum of rheumatological diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 165-171.	3.3	100

#	ARTICLE	IF	CITATIONS
19	Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. <i>Rheumatology International</i> , 2014, 34, 1103-1110.	3.0	99
20	Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. <i>Rheumatology</i> , 2009, 48, 834-839.	1.9	94
21	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. <i>Journal of Rheumatology</i> , 2012, 39, 849-855.	2.0	94
22	Longterm Retention of Tumor Necrosis Factor- α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	2.0	87
23	Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. <i>RMD Open</i> , 2017, 3, rmdopen-2017-000472.	3.8	84
24	Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. <i>Autoimmunity Reviews</i> , 2011, 10, 150-154.	5.8	83
25	Different effects of biological drugs in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 575-579.	5.8	76
26	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 835-839.	5.8	75
27	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019, 18, 102398.	5.8	75
28	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020, 50, 1085-1090.	0.8	75
29	Five-Year Follow-Up by Transesophageal Echocardiographic Studies in Primary Antiphospholipid Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 574-579.	1.6	72
30	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010, 9, 849-852.	5.8	65
31	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , 2008, 10, R51.	3.5	64
32	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 69-82.	3.0	64
33	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019, 18, 583-592.	5.8	64
34	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 90-96.	6.5	63
35	Rheumatic manifestations in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 20-23.	5.8	61
36	Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia. <i>Arthritis and Rheumatology</i> , 2017, 69, 2144-2150.	5.6	59

#	ARTICLE	IF	CITATIONS
37	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	8.0	57
38	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2007, 6, 529-536.	5.8	50
39	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 431-437.	5.8	50
40	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. <i>BioDrugs</i> , 2020, 34, 415-422.	4.6	50
41	Multidisciplinary approach to fibromyalgia: What is the teaching?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 311-319.	3.3	49
42	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBcâ€“positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016, 43, 869-874.	2.0	49
43	Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. <i>Arthritis Research and Therapy</i> , 2009, 11, R125.	3.5	48
44	Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN- β , and IFN- γ . <i>Cellular Immunology</i> , 2002, 220, 20-29.	3.0	46
45	Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 1661-1664.	2.0	46
46	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 277.	2.4	44
47	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	2.4	44
48	Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2002, 3, 18.	1.9	43
49	The Effect of Tumor Necrosis Factor- α Antagonists on Arterial Stiffness in Rheumatoid Arthritis: A Literature Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 1-8.	3.4	42
50	Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 649-657.	3.0	41
51	IL-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab. <i>Pharmacological Research</i> , 2019, 149, 104402.	7.1	41
52	Autoantibody production in patients treated with anti-TNF- α . <i>Expert Review of Clinical Immunology</i> , 2008, 4, 275-280.	3.0	40
53	Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. <i>Autoimmunity Reviews</i> , 2010, 9, 801-803.	5.8	40
54	Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. <i>Arthritis Care and Research</i> , 2013, 65, 274-280.	3.4	40

#	ARTICLE	IF	CITATIONS
55	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , 2018, 17, 33-35.	5.8	40
56	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	3.5	40
57	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018, 17, 24-28.	5.8	39
58	From autoinflammation to autoimmunity: old and recent findings. <i>Clinical Rheumatology</i> , 2018, 37, 2305-2321.	2.2	39
59	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. <i>Drug Safety</i> , 2018, 41, 1013-1022.	3.2	38
60	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity? Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	3.5	38
61	Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 500-510.	3.3	37
62	A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. <i>Pain and Therapy</i> , 2018, 7, 163-177.	3.2	37
63	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. <i>Pain and Therapy</i> , 2021, 10, 287-314.	3.2	37
64	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
65	Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. <i>Immunotherapy</i> , 2015, 7, 353-361.	2.0	35
66	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 517-524.	3.1	35
67	Infections in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 323-330.	4.3	34
68	Switching rheumatoid arthritis treatments: An update. <i>Autoimmunity Reviews</i> , 2011, 10, 397-403.	5.8	33
69	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e54-e54.	0.9	33
70	Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. <i>Rheumatology</i> , 2020, 59, 3042-3049.	1.9	33
71	The heart in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2010, 9, 414-418.	5.8	32
72	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	5.8	32

#	ARTICLE	IF	CITATIONS
73	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , 2021, 23, 6.	4.7	32
74	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.8	32
75	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 589-592.	5.8	31
76	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2013, 7, 69.	3.2	31
77	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , 2020, 15, e0235326.	2.5	31
78	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2007, 6, 553-558.	5.8	30
79	Is fibromyalgia a discrete entity?. <i>Autoimmunity Reviews</i> , 2012, 11, 585-588.	5.8	30
80	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 1115-1117.	5.8	30
81	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 186-193.	0.8	29
82	Imaging of diffuse idiopathic skeletal hyperostosis (DISH). <i>RMD Open</i> , 2020, 6, e001151.	3.8	28
83	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 712-714.	0.9	27
84	Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. <i>Journal of Pain Research</i> , 2016, 9, 279.	2.0	26
85	Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2017, 69, 1407-1413.	3.4	26
86	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018, 57, 1982-1990.	1.9	26
87	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	5.8	25
88	Pain in systemic inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 42-52.	3.3	25
89	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. <i>Joint Bone Spine</i> , 2014, 81, 37-40.	1.6	23
90	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , 2021, 60, 4844-4849.	1.9	23

#	ARTICLE	IF	CITATIONS
91	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S7-14.	0.8	23
92	How to measure chronic pain: New concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 164-186.	3.3	22
93	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the <sc>LORHEN</sc> registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 422-430.	1.9	22
94	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020, 161, 105206.	7.1	22
95	Anti-cytokine antibodies for rheumatic diseases. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1204-11.	2.3	21
96	Doctors' Insights into the Patient Perspective: A Qualitative Study in the Field of Chronic Pain. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	20
97	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1019-1032.	3.0	20
98	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre real-life cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	3.0	20
99	Preclinical Impairment of Coronary Flow Reserve in Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 392-397.	3.8	19
100	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
101	Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. <i>World Journal of Gastroenterology</i> , 2009, 15, 2469.	3.3	19
102	Clinimetric evaluations of patients with chronic widespread pain. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 249-270.	3.3	18
103	Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199325.	2.7	18
104	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	2.4	18
105	Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 731-8.	0.8	18
106	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 53.	3.2	17
107	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018, 57, vii11-vii22.	1.9	17
108	Behçet disease: From pathogenesis to novel therapeutic options. <i>Pharmacological Research</i> , 2021, 167, 105593.	7.1	17

#	ARTICLE	IF	CITATIONS
109	Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 233-244.	3.0	17
110	Serological epitope profile of anti-Ro52â€“positive patients with systemic autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2015, 17, 365.	3.5	16
111	A possible link between ankylosing spondylitis and periodontitis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2015, 54, 500-510.	1.9	16
112	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 945-956.	3.0	16
113	Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. <i>Journal of Medical Case Reports</i> , 2018, 12, 154.	0.8	16
114	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , 2019, 148, 104394.	7.1	16
115	Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 141-153.	5.8	16
116	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Stillâ€™s disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	1.9	16
117	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	1.6	15
118	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
119	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 845-848.	5.8	14
120	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
121	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020, 40, 101-113.	2.5	14
122	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1227.	2.4	14
123	Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Pain and Therapy</i> , 2021, 10, 577-588.	3.2	14
124	Cannabis and Autoimmunity: Possible Mechanisms of Action. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 261-271.	5.8	14
125	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , 2021, 60, SI25-SI36.	1.9	13
126	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2020, 18, 566-579.	1.7	13

#	ARTICLE	IF	CITATIONS
127	The role of echocardiographic techniques in connective tissue diseases. <i>Autoimmunity Reviews</i> , 2005, 4, 171-177.	5.8	12
128	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012, 51, 2141-2145.	1.9	12
129	The impact of pain on systemic rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 1-5.	3.3	12
130	Rheumatic diseases and autoimmune vascular dementia. <i>Autoimmunity Reviews</i> , 2017, 16, 1265-1269.	5.8	12
131	The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2020, 47, 1198-1203.	2.0	12
132	Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 33-37.	0.2	12
133	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	2.2	12
134	Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, 759-62.	0.8	12
135	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
136	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
137	An update on emerging drugs for fibromyalgia treatment. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 357-367.	2.4	11
138	Comment on: Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status: reply. <i>Rheumatology</i> , 2020, 59, e81-e81.	1.9	11
139	Concerns about the safety of anti-TNF agents when treating rheumatic diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 695-705.	2.4	11
140	Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain. <i>Pain Research and Management</i> , 2021, 2021, 1-7.	1.8	11
141	Rate of serious infections in spondyloarthritis patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 649-655.	0.8	10
142	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: A prospective long-term follow-up. <i>Autoimmunity</i> , 2008, 41, 87-91.	2.6	9
143	Resistant Cases of Psoriatic Arthritis: How to Manage Them. <i>Journal of rheumatology Supplement</i> , The, 2009, 83, 73-75.	2.2	9
144	Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. <i>BMC Medical Education</i> , 2015, 15, 89.	2.4	9

#	ARTICLE	IF	CITATIONS
145	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 79-81.	2.2	9
146	Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. <i>Future Science OA</i> , 2019, 5, FSO396.	1.9	9
147	Microbial Agents as Putative Inducers of B Cell Lymphoma in Sjögren's Syndrome through an Impaired Epigenetic Control: The State-of-The-Art. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	2.2	9
148	Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis. <i>Immunotherapy</i> , 2020, 12, 749-756.	2.0	9
149	The contribution of HERV clone 4 and other HERV members to the pathogenesis of rheumatic autoimmune diseases. <i>Apmis</i> , 2020, 128, 367-377.	2.0	9
150	One year in review 2019: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 3-10.	0.8	9
151	Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 31-39.	0.8	9
152	Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 213-222.	3.0	8
153	Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	8
154	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab BiosimilAr). <i>Internal and Emergency Medicine</i> , 2021, 16, 149-156.	2.0	8
155	Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?. <i>Frontiers in Medicine</i> , 2021, 8, 735150.	2.6	8
156	Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 26.	2.6	7
157	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102401.	5.8	7
158	Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance. <i>Current Rheumatology Reviews</i> , 2018, 14, 131-139.	0.8	7
159	Novel pharmaceutical options for treating fibromyalgia. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 559-565.	3.1	6
160	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
161	Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study. <i>Clinical Rheumatology</i> , 2019, 38, 2541-2546.	2.2	6
162	Severe bitter taste associated with apremilast. <i>Dermatologic Therapy</i> , 2019, 32, e12876.	1.7	6

#	ARTICLE	IF	CITATIONS
163	The effect of drugs used in rheumatology for treating SARS-CoV2 infection. Expert Opinion on Biological Therapy, 2021, 21, 219-228.	3.1	6
164	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	2.2	6
165	Usefulness of six-minute walk test in systemic sclerosis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 161-167.	0.8	6
166	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 97-106.	0.8	6
167	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 123, 53-59.	0.8	6
168	Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia. Stress and Health, 2021, 37, 255-262.	2.6	5
169	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. Rheumatology Advances in Practice, 2021, 5, rkab015.	0.7	5
170	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs in Context, 2021, 10, 1-13.	2.2	5
171	Adult-onset Still's disease with elderly onset, results from a multicentre study. Clinical and Experimental Rheumatology, 2022, , .	0.8	5
172	Why wait? Explaining delays in seeking therapy for early arthritis. Nature Reviews Rheumatology, 2012, 8, 190-191.	8.0	4
173	Controlled-release pregabalin in the treatment of fibromyalgia. Expert Review of Neurotherapeutics, 2018, 18, 617-623.	2.8	4
174	Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. Clinical Chemistry and Laboratory Medicine, 2020, 58, e105-e108.	2.3	4
175	New biological treatments for psoriatic arthritis. Israel Medical Association Journal, 2014, 16, 643-5.	0.1	4
176	The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 72-77.	0.8	4
177	Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39, 120-127.	0.8	4
178	IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?. Expert Opinion on Biological Therapy, 2022, 22, 843-853.	3.1	4
179	The therapeutic journey of biologic agents: There will be an end?. Pharmacological Research, 2019, 147, 104340.	7.1	3
180	Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis. Pharmacological Research, 2020, 158, 104507.	7.1	3

#	ARTICLE	IF	CITATIONS
181	The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3619.	2.4	3
182	Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 845-867.	4.1	3
183	<p>Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 13-21.	3.2	3
184	Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 63-69.	0.8	3
185	Hyperbaric oxygen therapy in fibromyalgia and the diseases involving the central nervous system. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 94-98.	0.8	3
186	Infections during treatment with biological agents and possible treatment in clinical practice. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 193-195.	3.0	2
187	Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?. <i>Cytokine and Growth Factor Reviews</i> , 2019, 49, 42-58.	7.2	2
188	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , 2020, 87, 507-508.	1.6	2
189	Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçetâ€™s Syndrome. <i>Clinical Neurology and Neurosurgery</i> , 2020, 191, 105680.	1.4	2
190	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 127-131.	0.8	2
191	Evaluation of salivary and plasma microRNA expression in patients with Sjögren's syndrome, and correlations with clinical and ultrasonographic outcomes. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 70-77.	0.8	2
192	Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 125-132.	0.8	2
193	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 245-256.	0.8	2
194	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.8	2
195	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.8	2
196	Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. <i>Israel Medical Association Journal</i> , 2021, 23, 344-349.	0.1	2
197	Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 1029.	2.4	2
198	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2

#	ARTICLE	IF	CITATIONS
199	Autoimmunity and the Newer Biopharmaceuticals. , 2014, , 795-802.		1
200	Toxicological considerations in the treatment of axial spondylo-arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 663-672.	3.3	1
201	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. Acta Biomedica, 2021, 92, e2021238.	0.3	1
202	Neuromuscular efficiency in fibromyalgia is improved by hyperbaric oxygen therapy: looking inside muscles by means of surface electromyography. Clinical and Experimental Rheumatology, 2019, 37 Suppl 116, 75-80.	0.8	1
203	Fibromyalgia position paper. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 186-193.	0.8	1
204	One year in review 2021: fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 3-12.	0.8	1
205	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. Clinical and Experimental Rheumatology, 2022, , .	0.8	1
206	JAK inhibitors: special issue foreword. Expert Review of Clinical Immunology, 2022, 18, 179-180.	3.0	1
207	Onset and temporal sequencing patterns of comorbidity between lifetime major depression, panic disorder and fibromyalgia. Clinical and Experimental Rheumatology, 0, , .	0.8	1
208	Diagnosis of cardiac involvement in systemic autoimmune diseases. Expert Review of Clinical Immunology, 2007, 3, 839-843.	3.0	0
209	Echocardiographic approach in systemic autoimmune diseases. Journal of Cardiovascular Echography, 2011, 21, 152-156.	0.4	0
210	Helicobacter pylori Infection and Gastric Autoimmunity. , 2015, , 495-503.		0
211	Neurobiological similarities between RA and fibromyalgia. Nature Reviews Rheumatology, 2018, 14, 324-325.	8.0	0
212	AB1106â€¦PREVALENCE AND EPIDEMIOLOGY OF FAMILIAL MEDITERRANEAN FEVER AND TUMOR NECROSIS FACTORRECEPTOR-ASSOCIATED PERIODIC SYNDROME: RESULTS FROM AN ITALIAN CENTER. , 2019, , .		0
213	Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases. Drugs in Context, 2021, 10, 1-9.	2.2	0
214	PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in BehÃ§et's disease. Clinical and Experimental Rheumatology, 2011, 29, S38-43.	0.8	0
215	Metabolic Syndrome in Systemic Sclerosis Patients: Data from Clinical Practice. Israel Medical Association Journal, 2021, 23, 262-263.	0.1	0
216	Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 120-127.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Title is missing!. , 2020, 15, e0235326.		0
218	Title is missing!. , 2020, 15, e0235326.		0
219	Title is missing!. , 2020, 15, e0235326.		0
220	Title is missing!. , 2020, 15, e0235326.		0
221	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0